An Expert Looks to the Future of Metastatic Kidney Cancer Treatment

When it comes to current treatments that are available for patients with newly diagnosed metastatic renal cell carcinoma (mRCC), Dr. Toni K. Choueiri, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, and senior physician at Dana-Farber Cancer Institute in Boston, notes that there are quite a few options in existence, with more on the way.

In a recent interview with CURE®’s sister publication, OncLive®, Choueiri, who is also the Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School, discussed not only the current treatment options for patients with mRCC, but those that could be viable in the near future once current trials are concluded.

Transcription:

Absolutely. I think now we're entering in an era of combination therapy, where single agent tyrosine kinase inhibitors are being given less and less.

We have an FDA approved regimen in the past couple of years (of) nivolumab and ipilimumab, intravenous immune-oncology drug, but also axitinib in combination with the PD1 inhibitor pembrolizumab or the PDL1 inhibitor avelumab.

We also have a single agent cabozantinib that also showed superiority over sunitinib in a randomized trial by the name CABOSUN.

The therapies overall in metastatic disease are still evolving, because there are trials that are finished accrual and reading, or just about to read, and may add more options this to this list.